ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0595

bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis

Sélina HANNA ABDELMASSIH1, Tiphaine DUJARDIN2, Athan BAILLET1, Philippe GAUDIN1 and Xavier ROMAND1, 1Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, 2Hôpital Reine Hortense, Aix-les-Bains, France

Meeting: ACR Convergence 2024

Keywords: Anti-TNF Drugs, biologic response modifiers, Disease-Modifying Antirheumatic Drugs (Dmards), meta-analysis, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Treatment Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving a questionable place of methotrexate (MTX) use in treatment strategies. Long-term therapy is impaired by treatment discontinuation and loss of effectiveness. Combination therapy with MTX have proven to improve drug survival in rheumatic diseases such as rheumatoid arthritis. This article reviews the available data on bDMARD drug survival when used combined with MTX in PsA.

Methods: We identified studies answering our research question through a comprehensive, systematic literature search using predefined search criteria. All databases (PubMed, Embase, Cochrane) were thus searched to identify all pertinent articles up till December 2023. Studies were screened by title and abstract then further by full‐text review. Hazard ratio (HR) data were extracted. Where applicable, HRs values were estimated directly from published Kaplan–Meier drug survival curves using the method of Parmar et al. study (1) 1998, Stats in Med 2815-2834). We considered HRs > 1.0 to be in favour of monotherapy, and HRs < 1.0 to be in favour of combination therapy. Meta-analyses were completed using Review Manager 5.4 with a random-effect model and inverse-variance method. Sensitivity analyses were conducted using a leave-one-out method to determine the effect of each study on the reliability of overall pooled effect sizes.

Results: 542 records were identified through database searching. Nineteen studies were included, with a total of 28,340 patients with PsA. All studies were observational. Only two studies involved bDMARDs other than TNF inhibitors (TNFi). PsA diagnosis were based on CASPAR criteria or left to clinician discretion. Combination therapy with MTX was found to be associated with a superior drug survival  (HR = 0.81 [IC95%, 0.75, 0.89], p-value < 0.00001, I2=48%) When the two studies evaluating drug survival of non TNFi bDMARDs were excluded, our finding remains in favour of combination therapy with MTX (HR=0.79 [IC95%, 0.73, 0.86], p-value < 0.00001, I2=30%). All studies were at an overall moderate risk of bias given the methodological similarities. 

Conclusion: This meta-analysis suggests the positive impact of MTX on bDMARD drug survival, especially with TNFi. Further studies are needed to confirm this hypothesis with robust evidence such as randomised controlled trials.

Supporting image 1

bDMARD drug survival in combination therapy with MTX (Meta-Analysis)


Disclosures: S. HANNA ABDELMASSIH: None; T. DUJARDIN: None; A. BAILLET: None; P. GAUDIN: None; X. ROMAND: None.

To cite this abstract in AMA style:

HANNA ABDELMASSIH S, DUJARDIN T, BAILLET A, GAUDIN P, ROMAND X. bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/bdmard-drug-survival-in-combination-therapy-with-methotrexate-in-psoriatic-arthritis-a-systematic-literature-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bdmard-drug-survival-in-combination-therapy-with-methotrexate-in-psoriatic-arthritis-a-systematic-literature-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology